Baird analyst Michael Ha has maintained a Neutral rating on Elevance Health and raised the price target to $393 from $331. The adjustment reflects a revised valuation outlook for the company's shares. Separately, RBC Capital analyst Ben Hendrix maintained a Sector Perform rating on Elevance Health and raised the price target to $439 from $358. Cantor Fitzgerald analyst Sarah James maintained an Overweight rating with a price target of $450, up from $400, indicating a more bullish stance compared to the market performance expectation at RBC Capital. Leerink Partners analyst Whit Mayo maintains Elevance Health with a Market Perform and raises the price target from $364 to $395.

Elevance Health trades on the NYSE under the ticker symbol ELV.

RBC Capital analyst Ben Hendrix has maintained a Sector Perform rating on Elevance Health while lowering the price target to $424 from the previous $439. This adjustment adds to a divergent set of outlooks on Wall Street, contrasting with recent positive revisions from other major firms. While RBC's revision suggests a more cautious stance on valuation or growth trajectory, other analysts have raised their targets, reflecting a generally strong bullish sentiment for the stock.

Rating and Price Action

Despite the downward revision from RBC Capital, other firms have recently increased their price targets. TD Cowen analyst Ryan Langston maintained a Buy rating and raised the price target to $465 from $400. Similarly, Truist Securities analyst David Macdonald kept a Buy rating, increasing the target to $475 from $450. Wells Fargo analyst Stephen Baxter also maintained an Overweight rating with a revised price target of $492, up from $391. Barclays analyst Andrew Mok maintained an Overweight rating but lowered the price target to $457 from $480.

Key Details